Login / Signup

An alternatively transcribed TAZ variant negatively regulates JAK-STAT signaling.

Chuantao FangJian LiSixian QiYubin LeiYan ZengPengcheng YuZhaolan HuYufeng ZhouYulong WangRuping DaiJin LiShenglin HuangPing-Long XuKang ChenChen DingFa-Xing Yu
Published in: EMBO reports (2019)
Type I interferon (IFN)-induced Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling drives the expression of IFN-stimulated genes (ISGs) to mediate antiviral response. The strength and duration of JAK-STAT signaling are tightly regulated to ensure effective antiviral defense while avoiding pathological inflammation and autoimmunity. Here, we report that cTAZ, an isoform of the Hippo pathway effector TAZ, is transcribed by an alternative promoter. Although majority of C-terminal sequences of TAZ is retained, cTAZ is not regulated by the Hippo signaling and does not mediate its growth-inhibitory functions. Instead, cTAZ negatively regulates JAK-STAT signaling by inhibiting STAT1/2 nuclear localization and ISG expression, and its expression is induced by type I IFN Thus, cTAZ functions as a modulator of JAK-STAT signaling and may play a role in fine-tuning cellular antiviral response.
Keyphrases
  • poor prognosis
  • dendritic cells
  • immune response
  • transcription factor
  • regulatory t cells
  • drug induced
  • endothelial cells
  • genetic diversity
  • bioinformatics analysis